Bypassing the Need for and Avoiding the Risks of Covid-19 Vaccines

The warp speed development of an anti-Covid-19 vaccine disregards the non-immunological anti-virus defense mechanism mediated by the alternative cellular energy (ACE) pathway. This pathway was identified in studies on stealth adapted viruses. These viruses have deletions or mutations in the genes coding for the relatively few virus components that are normally targeted by the cellular immune system. Public Health authorities have denied the existence of these viruses because some were originally derived from the viruses that infect the monkeys used to produce polio vaccines. A novel feature of the stealth adaption process is that in addition to losing certain genes, there can be the incorporation of genetic sequences from infected cells. This has allowed the transmission to humans of monkey cellular genes. gatwick pcr test 

Even though the immune system is restricted in its capacity to suppress stealth adapted viruses, these viruses and indeed potentially all viruses, can still be suppressed providing the infected cells have sufficient cellular energy. Symptomatic Covid-19 infection is, therefore, an indication that the person’s cells have insufficient cellular energy. Conversely, symptomatic infections can be prevented by enhancing the cellular energy of those exposed to the virus. Arguably, this can be achieved by the repeated inhalation of the mist generated by inhaling nebulizing water with a heightened level of a natural energy referred to as KLELEA, an abbreviation for Kinetic Energy limiting Electrostatic Attraction. A natural source of KELEA activated water has been identified in Southern California. It can also be generated using a number of simple procedures. The current investigative protocol is to inhale the mist from 5 ml of activated water, over a 5-minute period for 5 times a day for two days. The primary outcome is the conversion from a positive PCR or antigen test prior to the two-day inhalation to a negative test following the investigational procedure. A secondary outcome is self-reported assessments of changes in symptom severity. This study is registered at ww.clinicaltrials.gov identification number NCT04490824.

Stealth adapted virus-infected individuals are at a special risk from receiving a Covid-19 vaccine. First, the non-specific immune stimulation from the vaccine can enable immune reactivity against some of the residual components on the stealth adapted viruses. If these viruses reside in the central nervous system, the resulting inflammation can present as multiple sclerosis or transverse myelitis, as has been reported using the AstraZeneca vaccine. Second, stealth adapted viruses can incorporate and become carriers of foreign genes. Were preexisting stealth adapted viruses to incorporate the vaccine Covid-19 spike antigen-coding DNA or RNA sequence, they could readily disrupt the body’s angiotensin-mediated regulatory system. It is highly unlikely that these considerations are being addressed by either the Food and Drug administration (FDA) or vaccine manufacturers. Indeed as noted above, the FDA, and even the National Institutes of Health (NIH),have refused to even acknowledge the existence of monkey-derived stealth adapted viruses in spite of overwhelming DNA sequence data on these viruses.